Maze Therapeutics (MAZE) Income Statement (2024 - 2026)
Income Statement report data from Mar 31, 2024 to Mar 31, 2026 for Maze Therapeutics (MAZE).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||
Total Revenue | 20M | - | - | - | - | - | 2.50M (-98.48%) | 165M | - |
Operating Expenses | |||||||||
Research And Development | 34M (+23.87%) | 28M (+9.45%) | 25M (-10.39%) | 28M (+1.92%) | 28M (+24.12%) | 22M (+11.88%) | 20M (+1.59%) | 20M (-10.65%) | 22M |
Selling General And Administrative | 12M (+18.30%) | 10M (+34.83%) | 7.78M (-7.05%) | 8.37M (+7.03%) | 7.82M (+4.13%) | 7.51M (+9.32%) | 6.87M (+16.44%) | 5.90M (-3.91%) | 6.14M |
Operating Expenses | 47M (+22.31%) | 38M (+15.44%) | 33M (-9.60%) | 36M (+3.02%) | 35M (+19.07%) | 30M (+11.22%) | 27M (+5.03%) | 25M (-9.14%) | 28M |
Depreciation And Amortization | 440K (-74.42%) | 1.72M | - | - | 680K (-71.06%) | 2.35M | - | - | 950K |
Operating Income | |||||||||
Operating Income | -26.55M (-30.24%) | -38.06M (+15.44%) | -32.97M (-9.60%) | -36.47M (+3.02%) | -35.40M (+19.07%) | -29.73M (+22.70%) | -24.23M | 140M | -28.01M |
Ebit | -26.55M (-30.24%) | -38.06M (+15.44%) | -32.97M (-9.60%) | -36.47M (+3.02%) | -35.40M (+19.07%) | -29.73M (+22.70%) | -24.23M | 140M | -28.01M |
EBITDA | -26.11M (-37.85%) | -42.01M (+39.61%) | -30.09M (-10.66%) | -33.68M (-3.00%) | -34.72M (+24.89%) | -27.80M (+11.07%) | -25.03M | 141M | -27.06M |
Other Income / Expenses | |||||||||
Interest Expense | 870K | - | - | - | - | - | - | - | - |
Other Non Operating Income | 2.35M | - | - | - | 2.62M | - | - | - | - |
Net Income | |||||||||
Income Before Tax | - | -34.57M (+14.89%) | -30.09M (-10.66%) | -33.68M (+2.71%) | -32.79M (+9.85%) | -29.85M (+19.26%) | -25.03M | 141M | -32.49M |
Income Tax Expense | - | - | - | - | - | -280.00K (0.00%) | -280.00K | 1.73M | - |
Net Income From Continuing Operations | -24.21M (-29.97%) | -34.57M (+14.89%) | -30.09M (-10.66%) | -33.68M (+2.71%) | -32.79M (+10.85%) | -29.58M (+19.52%) | -24.75M | 139M | -32.49M |
Net Income | -24.21M (-29.97%) | -34.57M (+14.89%) | -30.09M (-10.66%) | -33.68M (+2.71%) | -32.79M (+10.85%) | -29.58M (+19.52%) | -24.75M | 139M | -32.49M |
Comprehensive Income Net Of Tax | -24.45M (-81.34%) | -131.01M (+336.41%) | -30.02M | - | -32.79M | 52M | -24.75M | - | - |